

5 August 2016

Attention: Chair and Members,  
Australian Medical Research Advisory Board  
c/- MRFF@health.gov.au

## **Burden of musculoskeletal conditions**

At recent public consultations on the strategy and priorities for the Medical Research Future Fund, questions were raised about the accuracy of the burden of disease estimates for musculoskeletal conditions being used by the Advisory Board in its deliberations. As requested by Advisory Board members, we are writing to provide you with the most up to date data on the burden of these conditions.

Arthritis Australia made a submission through the formal processes but burden of disease data was not provided, as instructions specifically requested that this information not be included.

The signatories to the attached submission represent peak organisations and world-leading individuals working in musculoskeletal care, research and consumer advocacy.

The most recent estimates of burden of disease for Australia are available from the Global Burden of Disease Study (2012)<sup>1, 2</sup> and from the 2016 Australian Burden of Disease Study.<sup>3</sup>

Both of these studies show that the total burden of musculoskeletal conditions is between 12-14% of the total burden of disease in Australia. These estimates are much higher than the 4% estimated in the 2007 Australian Burden of Disease Study,<sup>4</sup> which appears to be the data being used by the Advisory Board.

The increase in burden for musculoskeletal conditions since the 2007 report appears to be due primarily to improved methodology rather than an increase in burden, indicating that the burden of musculoskeletal conditions has been underestimated and overlooked in Australia for too long. This has resulted in a substantial gap between disease burden and research funding, creating inequity for the millions of people living with these conditions as well as a significant area of unmet need.

As the attached submission demonstrates, by any metric, be it total burden of disease, prevalence, cost, disability, quality of life, productivity and economic impact, or future impact due to an ageing population, there is an urgent need to prioritise research on the most effective and affordable strategies to deal with musculoskeletal conditions.

We strongly urge the Advisory Group to include musculoskeletal conditions as a priority in the Australian Medical Research and Innovation Strategy (the Strategy).

Yours sincerely



**Ainslie Cahill**  
CEO  
Arthritis Australia



**Professor Rachelle Buchbinder**  
President, Australian Rheumatology Association  
Founding Member and Chair, Executive Committee,  
Australia & New Zealand Musculoskeletal  
(ANZMUSC) Clinical Trials Network



**Professor Lyn March**  
Liggins Professor of Rheumatology and  
Musculoskeletal Epidemiology, University  
of Sydney  
Chair, AIHW National Arthritis and other  
Musculoskeletal Conditions Monitoring  
Advisory Group



**Professor David Hunter**  
Chair  
Institute of Bone and Joint Research




**Professor Chris Maher**  
Director, Musculoskeletal Division, The  
George Institute for Global Health



**Dr Dominic Thewlis**  
President of the Australian & New Zealand  
Orthopaedic Research Society



**Linda Bradbury**  
Nurse Practitioner - Rheumatology  
Rheumatology Health Professionals  
Association (RHPA) President



**A/Prof Davinder Singh-Grewal**  
Chair  
Australian Paediatric Rheumatology Group



**Professor Christopher Little, BVMS, PhD**  
Director, Raymond Purves Bone and Joint  
Research Laboratories



**Cris Massis**  
Chief Executive Officer  
Australian Physiotherapy Association

# Submission to the consultation on the Australian Medical Research and Innovation Strategy and related Priorities

## The Burden of Musculoskeletal Conditions in Australia

### Summary of key points

- Musculoskeletal conditions in Australia are:
  - the most common and disabling of all chronic conditions, affecting nearly 7 million people and accounting for at least 31% of disability;
  - the fourth most costly disease group in the health system, at a cost \$5.7 billion in 2008-09;
  - a major drain on economic productivity as the leading cause of early retirement due to ill-health.
- The most recent **global burden of disease** estimates for Australia (published in 2012) show musculoskeletal conditions:
  - account for 13.63% of the total disease burden (DALYs), in close third place after cancer (15.7%) and mental health and substance abuse (13.66%);
  - are the leading cause of non-fatal burden, accounting for 24% of total YLDs.
- The most recent **Australian burden of disease** study (published by AIHW in 2016) shows musculoskeletal conditions:
  - are the fourth leading cause of total disease burden in Australia (DALYs), accounting for 12% of the burden (very close to mental health conditions);
  - the second leading cause of non-fatal burden (YLDs) (23%) after mental health and substance abuse (24%), but the leading cause in women.
- Research funding for musculoskeletal conditions is disproportionately low relative to the disease burden and cost of these conditions.
  - NHMRC funding for the musculoskeletal National Health Priority Area in 2015 was just 3.5% of total NHPA funding, or about one quarter of the estimated disease burden
  - Clinical research funding for these conditions is also disproportionately low at about 5% of total NHMRC funding for clinical trials.

### Conclusion


- Musculoskeletal conditions should be a priority area for research funded from the MRFF supported by:
  - Priority setting to identify key research areas
  - Targeted calls for research
  - Dedicated research and practitioner fellowships to build research capacity
  - Funding for Centres of Research Excellence and Partnership Programs to improve clinical interventions and management and provide health work force education
  - Funding for research infrastructure such as patient databases to support research into causes and potential cures.

# The Burden of Musculoskeletal Conditions in Australia

## 1. Cost, prevalence and impact

Musculoskeletal conditions encompass a number of conditions including back pain, neck pain, more than 100 forms of arthritis, and osteoporosis.


These conditions affect nearly 7 million Australians of all ages, including children.<sup>5</sup> They are the leading cause by far of disability (Figure 1)<sup>6</sup> and contribute to 1 in 20 deaths in Australia.<sup>7</sup>



Musculoskeletal conditions are the fourth most costly conditions to the health system, costing \$5.7 billion and accounting for nearly 9% of expenditure allocated to disease groups in 2008/09 (Figure 2).<sup>8</sup> More recent estimates show that arthritis alone costs the health system over \$5.5 billion in 2015 and this is projected to rise to \$7.6 billion by 2030 unless more is done to prevent and better manage this group of conditions.<sup>9</sup>

The impact on productivity is also substantial. Musculoskeletal conditions account for 41% of early retirements due to ill-health in Australians aged 45-64 years, at an annual cost of \$16 billion in lost GDP.<sup>10</sup>

Musculoskeletal conditions also cause more than 85% of chronic pain in Australia.<sup>11</sup> So it is surprising that chronic pain, but not musculoskeletal conditions, was suggested as a priority area for the Strategy during the Sydney consultation.



### Comorbidity

Another potential priority area raised during discussion at the Sydney consultation was management of co-morbid conditions. Arthritis and musculoskeletal conditions are important in this context. Three out of four people with arthritis have more than one co-morbid condition, most commonly cardiovascular disease, back problems and mental health problems.<sup>13</sup> Arthritis and back problems are also the most common co-morbidities in people with other major chronic conditions across all age groups.<sup>14</sup>

Musculoskeletal conditions significantly limit a person's ability to self-manage other chronic conditions because of their negative impact on physical activity and mental health, as well as adding complexity to general management. Yet they are often overlooked or given low priority as co-morbid conditions.

### Healthy ageing

Musculoskeletal conditions represent a global threat to healthy ageing, according to a report for the WHO on ageing and health.<sup>15</sup>

Musculoskeletal health is central to active healthy ageing. It is critical for people's mobility and their ability to work and actively participate in all aspects of life, and to maintain economic, social and functional independence across their life-course.

Musculoskeletal health enables physical activity to reduce the risk and support the management of other non-communicable diseases. A strong relationship exists between arthritis and musculoskeletal pain and a lack of physical activity in the elderly resulting in functional decline, frailty, loss of well-being and loss of independence.

Research into the prevention and management of musculoskeletal conditions across the life course will be crucial to enhance musculoskeletal health and prevent disability in older people and will be a critical to achieve healthy ageing objectives.<sup>15</sup>

## Osteoporosis


The burden of osteoporosis in Australia is commonly overlooked. In the 50+ population, 66% of people have poor bone health (osteoporosis or osteopenia).<sup>16</sup> 1.2 million Australians are affected by osteoporosis.<sup>17</sup> Patients with osteoporosis fracture easily at sites such as the hip, wrist and spine, and within a year of fracture 20% of patients die and half the remainder do not walk unaided.<sup>18</sup> Indeed, a single low trauma fracture doubles the risk of death for up to 10 years.<sup>19</sup> It is estimated that 155,000 fractures will occur in Australia in 2016 at a cost of \$3.185 billion (direct and indirect cost) and estimated costs of \$33.6 billion over 10 years (2013-2022).<sup>16</sup> Hip fracture remains the mostly costly type of fracture with average mean direct cost of hip fracture (aged 70+) of \$33,576 (\$2012).<sup>16</sup>

It is widely acknowledged there are significant gaps in Australia's health information infrastructure and in particular limited information on certain conditions including musculoskeletal conditions.<sup>20</sup> In addition AIHW acknowledges osteoporotic fracture data is under-reported.<sup>21</sup>

## 2. Burden of disease

### 2.1 Disability Adjusted Life Years (DALYs)

The most recent Global Burden of Disease Study<sup>1,2</sup> found that musculoskeletal conditions account for 13.63% of the total disease burden in Australia, in a close third place after cancer (15.7%) and mental health and substance abuse (13.66%) (Fig 3).



According to the AIHW<sup>3</sup>, musculoskeletal conditions are the fourth leading cause of disease burden in Australia, accounting for 12% of the total disease burden. This is much higher than the 4% estimate for these conditions in the 2007 Australian Burden of Disease study.<sup>4</sup>


For women, musculoskeletal conditions were second only to cancer as the leading cause of disease burden. At the disease level 'other musculoskeletal conditions', a group which largely consists of other forms of arthritis (other than osteoarthritis or rheumatoid arthritis) and related conditions, were the third leading cause of disease burden after heart disease and lung cancer.<sup>3</sup>

The burden of musculoskeletal conditions is significant across most ages: it is second only to mental and behavioural disorders from adolescence through to age 45 years and is the leading burden for those aged 45-55 years while cancer and cardiovascular disease become the leading causes of burden in older age groups.<sup>1,2,3</sup>

## 2.2 Years Lived with Disability (YLDs)

Musculoskeletal conditions are the leading cause of years lived with disability in Australia, accounting for 24% of total YLDs, according to the Global Burden of Disease study (Fig 4).

According to the AIHW, musculoskeletal conditions are the second leading cause overall of non-fatal burden (YLDs) (23%) after mental health and substance abuse (24%), but the leading cause in women.<sup>3</sup>




## 3. Research funding relative to disease burden


NHMRC data on research funding for National Health Priority Areas (NHPA)<sup>22</sup> shows that funding for the arthritis and musculoskeletal conditions NHPA totalled just \$23 million in 2015 or around 3.5% of total NHPA funding (Figure 5). This figure is much lower than the most recent estimate of 12% of total disease burden for musculoskeletal conditions. In comparison, research funding for diabetes represents 11% of total NHPA funding, compared to a total burden estimate of 2.4%.

In the last decade, research funding has grown by just 33% for the musculoskeletal NHPA while funding for NHPAs overall has nearly doubled (Figure 6).

With over 100 forms of arthritis and many musculoskeletal conditions, this low level of research investment cannot possibly hope to address the challenge of even the most common conditions. Less common conditions miss out altogether. For example, juvenile idiopathic arthritis, which is one of the most common chronic conditions of childhood and a focus area for the arthritis and musculoskeletal NHPA, receives negligible government funding for research and has only ever received one small NHMRC research funding grant.



**Figure 5: NHMRC funding for National Health Priority Areas 2015**



**Figure 6: Percentage increase in NHMRC funding by NHPA, 2005-06 to 2014-15**

Underfunding of arthritis and musculoskeletal research relative to other NHPAs is even more pronounced when you consider the total pool of research funding available, including funding from other sources. Funding for cancer research from government and non-government organisations for example totalled \$300 million in 2011,<sup>23</sup> \$125 million on top of the NHMRC allocation. The same year, the National Heart Foundation invested \$13 million in cardiovascular research.<sup>24</sup> In comparison, Arthritis Australia, the largest non-government provider of research funding for musculoskeletal conditions in Australia, was able to allocate only \$726,000 to arthritis research in 2012/13.

### 3.1 Clinical trials activity

Funding for MSK clinical trials in Australia is also disproportionately low compared to the burden of these conditions, representing just 5% of NHMRC clinical trial funding. This undermines our capacity to deliver best evidence-informed, cost-effective care and optimal outcomes for people living with these conditions.<sup>25</sup>

This conclusion has recently been re-affirmed. An analysis by Lam and colleagues<sup>26</sup> of clinical trials activity in Australia against burden of disease, based on 2003 estimates, initially concluded that the proportion of registered Australian arthritis and musculoskeletal trials was about twice as high as expected. However, in response, a re-analysis by Buchbinder, Maher and Harris<sup>27</sup> using the most recent Global Burden of Disease estimates came to the opposite conclusion (Table 1).

In acknowledging this re-analysis, Lam and colleagues concluded:

*‘Using the GBD 2010 estimates, musculoskeletal trial activity is 54% of expected for trial number and below 50% of expected for planned recruitment, ranking close to obesity and dementia as an area of need, with important implications for assigning research priorities’<sup>27</sup>*

**Table 1: Comparison of trial activity to disease burden for Australian National Health Priority Areas; trial activity and AIHW disease burden data are from Lam<sup>17</sup> and GBD data were accessed from <http://www.healthmetricsandevaluation.org> on July 21 2015**

| National Health Priority Area          | Trials (% of total) | Disease burden (% total DALYs) |          | Do GBD data change conclusion of matching of trial activity to disease burden? |
|----------------------------------------|---------------------|--------------------------------|----------|--------------------------------------------------------------------------------|
|                                        |                     | AIHW 2003                      | GBD 2010 |                                                                                |
| Cancer                                 | 16.9                | 19.0                           | 16.5     | Yes: trials match GBD burden                                                   |
| Cardiovascular                         | 12.6                | 18.0                           | 13.9     | No                                                                             |
| Mental health                          | 13.5                | 13.3                           | 12.9     | No                                                                             |
| Obesity                                | 3.8                 | 7.5                            | 8.5      | No                                                                             |
| Injury                                 | 2.7                 | 7.0                            | 9.9      | No                                                                             |
| Diabetes mellitus                      | 5.5                 | 5.5                            | 2.3      | Yes: trials exceed GBD burden                                                  |
| Arthritis & Musculoskeletal Conditions | 8.0                 | 4.0                            | 14.7     | Yes: trials are less than GBD burden                                           |
| Dementia                               | 1.3                 | 3.6                            | 2.4      | No                                                                             |
| Asthma                                 | 1.3                 | 2.4                            | 2.3      | No                                                                             |

## 4. Conclusion

Arthritis and musculoskeletal conditions are an existing National Health Priority Area (NHPA), but this has not been reflected in government investment in programs or research to address the growing burden, prevalence and expense of these conditions.

Research funding for arthritis and musculoskeletal conditions falls well short of the health and economic impact of these conditions. To address this issue, it is vital that the true burden

of musculoskeletal conditions is acknowledged by making them a priority area in the Medical Research and Innovation Strategy currently being developed for the MRFF.

As proposed in our original submission, this should include:

- Support for research priority setting to allow Australian researchers, clinicians, policymakers and consumers to work collaboratively to prioritise the most important research questions and undertake well designed trials to deliver best evidence-informed care and optimal outcomes for people with musculoskeletal conditions. Work in this area has been initiated by the recently formed Australian and New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC).
- Targeted calls for research proposals in the field to support funding for identified priority research questions
- Dedicated research and practitioner fellowships to build research capacity in the field
- Funding for Centres of Research Excellence and Partnership Programs to improve clinical interventions and management and provide health work force education
- Funding for research infrastructure such as patient databases to support research into causes and potential cures.

## **Supporting organisations**

Arthritis Australia

Australia and New Zealand Musculoskeletal Clinical Trials Network

Australian Rheumatology Association

Australian Paediatric Rheumatology Group

Rheumatology Health Professionals Association

Institute of Bone and Joint Research

Australia and New Zealand Orthopaedic Research Society

The George Institute for Global Health, Musculoskeletal Division,

## **Supporting individuals**

Professor Lyn March

Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, University of Sydney  
Chair, AIHW National Arthritis and other Musculoskeletal Conditions Monitoring Advisory Group

Professor Chris Little

Director, Raymond Purves Bone and Joint Research Laboratories  
Sub-Dean (Research), Sydney Medical School Northern Clinical School  
Associate Director Kolling Institute

## **Further information**

Franca Marine at [fmarine@arthritisaustralia.com.au](mailto:fmarine@arthritisaustralia.com.au)

- <sup>1</sup> Murray CJL et al 2012. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012; 380:2197-223
- <sup>2</sup> Global Burden of Disease Study 2013 Data Visualisations. Institute for Health Metrics and Evaluation, University of Washington, 2015 <http://vizhub.healthdata.org/gbd-compare/>
- <sup>3</sup> Australian Institute of Health and Welfare 2016. *Australian Burden of Disease Study: Impact and causes of illness and death in Australia 2011*. Australian Burden of Disease Study series no. 3. BOD 4. Canberra: AIHW
- <sup>4</sup> Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez AD, 2007. *The burden of disease and injury in Australia 2003*. PHE 82. Canberra: AIHW
- <sup>5</sup> ABS *National Health Survey First Results 2014-15*
- <sup>6</sup> ABS 2009. *Disability, Ageing and Carers, Australia: Summary of Findings, 2009*
- <sup>7</sup> Australian Institute of Health and Welfare 2016. *Musculoskeletal conditions as underlying and associated causes of death 2013*. Bulletin 136. Cat. no. AUS 203. Canberra: AIHW.
- <sup>8</sup> Australian Institute of Health and Welfare 2014. *Health-care expenditure on arthritis and other musculoskeletal conditions 2008-09*. Arthritis series no.20. Cat. no.PHE 177. Canberra: AIHW.
- <sup>9</sup> Schofield DJ, Shrestha RN, Cunich M 2016. *Counting the cost: the current and future burden of arthritis. Part 2 Economic Costs*. Arthritis Australia 2016.
- <sup>10</sup> Schofield DJ et al 2015. Lost productive life years caused by chronic conditions in Australians aged 45-64 years, 2010-2030. *MJA* 203 (6) 21 September 2015
- <sup>11</sup> Henderson JV, Harrison CM, Britt Hc, Bayram CF, Miller GC. Prevalence, causes, severity, impact and management of chronic pain in Australian general practice patients. *Pain Med* 2013 Sep; 14(9): 1346-61
- <sup>12</sup> Australian Institute of Health and Welfare 2014. *Health-care expenditure on arthritis and other musculoskeletal conditions 2008-09*. Arthritis series no.20. Cat. no.PHE 177. Canberra: AIHW.
- <sup>13</sup> <http://www.aihw.gov.au/arthritis-and-its-comorbidities/> Viewed 2/8/2016
- <sup>14</sup> <http://www.aihw.gov.au/chronic-diseases/common-comorbidities/> Viewed 2/8/2016
- <sup>15</sup> Briggs AM, Cross MJ, Hoy DG, Sanchez-Riera L, Blyth FM, March L 2016. Musculoskeletal health conditions represent a global threat to healthy aging: a report for the WHO World Report on Ageing and Health. *Gerontologist*. 2016 Apr;56 Suppl 2:S243-55. doi: 10.1093/geront/gnw002
- <sup>16</sup> Watts J, Abimanyi-Ochom J, Sanders K. Osteoporosis costing All Australians. A new Burden of Disease analysis 2012-2022. Prepared for Osteoporosis Australia 2013
- <sup>17</sup> Henry MJ, Pasco JA, Nicholson GC, Kotowicz MA. Prevalence of osteoporosis in Australian men and women: Geelong Osteoporosis Study. *MJA* September 19, 2011; 195 (6): 321-322.
- <sup>18</sup> Haentjens P1, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. *Ann Intern Med*. 2010 Mar 16;152(6):380-90.
- <sup>19</sup> Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. *JAMA*. 2009 Feb 4;301(5):513-21
- <sup>20</sup> Begg et al, Burden of disease and injury in Australia in the new millennium. *Med J Aust*, 2008; 188(1), 36-40
- <sup>21</sup> Australian Institute of Health and Welfare 2014. Estimating the prevalence of osteoporosis. Cat. no. PHE 178. Canberra: AIHW.(page 11).
- <sup>22</sup> <https://www.nhmrc.gov.au/grants-funding/research-funding-statistics-and-data> viewed 1/8/2016
- <sup>23</sup> Cancer Research Leadership Forum 2012. *Towards a national cancer research plan*. February 2012.
- <sup>24</sup> <http://www.heartfoundation.org.au/research/news/Pages/default.aspx> Viewed 15 March 2012.
- <sup>25</sup> Bourne AM, Whittle SL, Richards BL, Maher CG, Buchbinder R 2014. *MJA* 200 (2) 3 February 2014
- <sup>26</sup> Lam J, Lord SJ, Hunter KE, et al. Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority Areas. *Med J Aust* 2015; 203: 97-102.
- <sup>27</sup> Responses: Lam J, Lord SJ, Hunter KE, et al. Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority Areas. *Med J Aust* 2015; 203: 97-102.